First test of new drug for rare bleeding disorder
NCT ID NCT04770935
Summary
This was a very early, first-in-human study to see how the body processes a single dose of an experimental drug called BIVV001 and to check if it is safe. It involved just 6 adults with severe forms of a rare inherited bleeding disorder called von Willebrand disease. The main goal was to measure how long the drug stays active in the blood and to watch for any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VON WILLEBRAND'S DISEASE (VWD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hemophilia Center of Western Pennsylvania_Investigational Site Number :8400001
Pittsburgh, Pennsylvania, 15213, United States
-
Investigational Site Number :2500001
Lille, 59037, France
-
Investigational Site Number :2500002
Nantes, 44093, France
-
University of Iowa_Investigational Site Number :8400002
Iowa City, Iowa, 52242, United States
Conditions
Explore the condition pages connected to this study.